Loading organizations...
Loading organizations...
Elektrofi: Drug formulation and delivery technology platform for high-concentration subcutaneous biologics, partnering with biotech and pharma.
Based in Boston, Elektrofi develops proprietary drug formulation and delivery technologies that enable the subcutaneous administration of complex therapeutic molecules. The company's core Elektroject platform concentrates biologics by more than 15 times, creating stabilized formulations exceeding 400 milligrams per milliliter in small fluid volumes. This technological approach allows patients to receive monoclonal antibodies through quick injections rather than undergoing lengthy traditional intravenous clinical infusions. The enterprise operates primarily through strategic platform licensing agreements and collaborative drug development partnerships with major biopharmaceutical corporations, securing notable clients including LEO Pharma and Sanofi. Following successful validations of its delivery systems, the biotechnology firm Halozyme announced its definitive agreement to acquire the organization for $750 million in October 2025. Originating from research conducted at the Massachusetts Institute of Technology, Elektrofi was founded in 2016 by Chase Coffman and Jason Norris.
Elektrofi has raised $40.0M across 1 funding round.
Elektrofi has raised $40.0M in total across 1 funding round.
Elektrofi has raised $40.0M in total across 1 funding round.
Elektrofi's investors include Mark Nathan Lampert, Andrew Goldberg, Janus Henderson Investors, Logos Capital.
Elektrofi has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series B in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 13, 2022 | $40.0M Series B | Mark Nathan Lampert, Andrew Goldberg | Janus Henderson Investors, Logos Capital |